ISS Recommends Standard BioTools Stockholders Vote "FOR" All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif.

ISS Recommends Standard BioTools Stockholders

Vote "FOR" All Proposals Relating to Proposed Merger with SomaLogic

SOUTH SAN FRANCISCO, Calif. --

December 22, 2023 - Standard BioTools Inc. (Nasdaq: LAB),

driven by a bold purpose - Unleashing tools to accelerate breakthroughs in human health - today announced that

leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Standard BioTools

stockholders vote "FOR" all proposals relating to the pending merger with SomaLogic at the Company's upcoming Special

Meeting of Stockholders to be held on January 4, 2024. The Company issued the following statement:

Our merger with SomaLogic presents a compelling value proposition

for all stockholders through a significantly accelerated path to profitability and bolstered capital structure to fuel future growth.

We are pleased with ISS' recommendation and look forward to completing the merger in the first quarter of 2024.

A special meeting of Standard BioTools stockholders

is scheduled to be held virtually in connection with the proposed merger on January 4, 2024, at 12:00 p.m. ET (10:00 a.m. MT

/ 9:00 a.m. PT). Standard BioTools stockholders who need assistance voting or have questions regarding the Special Meeting may

contact Standard BioTools' proxy solicitor, Alliance Advisors LLC, at (800) 574-5969.

The merger remains on track to close in the first quarter

of 2024, subject to approval by SomaLogic and Standard BioTools stockholders and satisfaction of other customary closing conditions.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), previously known

as Fluidigm Corporation, is driven by a bold purpose - Unleashing tools to accelerate breakthroughs in human health. Standard BioTools

has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines

faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using

its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes.

Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories

worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Learn more at www.standardbio.com or connect with us on Twitter , Facebook , LinkedIn, and YouTube . Standard BioTools,

the Standard BioTools logo, Fluidigm, the Fluidigm logo, "Unleashing tools to accelerate breakthroughs in human health," Hyperion,

Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States

and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided

for Research Use Only. Not for use in diagnostic procedures.

Additional Information and Where to Find It

with the merger and required stockholder approval, Standard BioTools filed with the U.S. Securities and Exchange Commission (the

"SEC") a registration statement on Form S-4, as amended (the "Form S-4"), which was declared effective

by the SEC on December 1, 2023. The Form S-4 includes a definitive joint proxy statement of Standard BioTools and SomaLogic and

also constitutes a final prospectus of Standard BioTools. The definitive joint proxy statement was mailed or otherwise made available

to stockholders of Standard BioTools and SomaLogic on or about December 4, 2023. Standard BioTools'

and SomaLogic's stockholders are urged to carefully read the joint proxy statement/prospectus (including all amendments,

supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with the SEC and

in their entirety because they contain important information about the merger and the parties to the merger. Investors and stockholders

may obtain free copies of these documents and other documents filed with the SEC at its website at http://www.sec.gov.

In addition, investors may obtain free copies of the documents filed with the SEC by Standard BioTools at http://investors.standardbio.com or

contacting Standard BioTools' Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or

by contacting SomaLogic Investor Relations at investors@somalogic.com.

Participants in the Solicitation

Standard BioTools, SomaLogic and

each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from Standard

BioTools stockholders with respect to the merger. Information about Standard BioTools' directors and executive officers, including

their ownership of Standard BioTools' securities, is set forth in the joint proxy statement/prospectus, Standard BioTools'

proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current

Reports on Form 8-K, which were filed with the SEC on May 3, 2023, May 15, 2023, June 16,

2023 and July 28, 2023, and Standard BioTools' other filings with the SEC. Information concerning SomaLogic's

directors and executive officers, including their ownership of SomaLogic securities, is set forth in the joint proxy statement/prospectus,

SomaLogic's proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 25,

2023, Current Reports on Form 8-K, which were filed with the SEC on June 6, 2023, as amended on June 14,

2023, June 9, 2023, October 4, 2023 and December 12, 2023, and SomaLogic's other filings with the SEC.

Investors may obtain more detailed information regarding the direct and indirect interests of Standard BioTools and its respective

executive officers and directors in the merger, which may be different than those of Standard BioTools' stockholders generally,

by reading the definitive proxy statements regarding the merger, which have been filed with the SEC. These documents are available

free of charge at the SEC's website at www.sec.gov, at http://investors.standardbio.com or by contacting

Standard BioTools' Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or

by contacting SomaLogic Investor Relations at investors@somalogic.com.

No Offer or Solicitation

This press release and the

information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there

be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification

under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the

requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains

"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are

based upon current plans, estimates and expectations of the management of Standard BioTools and SomaLogic that are

subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many of which are

beyond the control of Standard BioTools and SomaLogic. All statements other than statements of historical fact (including

statements containing the words "believes," "plans," "anticipates," "expects," "estimates"

and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain

these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include

statements regarding the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the

various closing conditions; and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties'

current expectations and are necessarily subject to associated risks related to, among other things, (i) the risk that the Merger

may not be completed in a timely manner or at all, which may adversely affect Standard BioTools' and SomaLogic's businesses

and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the merger and the potential

failure to satisfy the conditions to the consummation of the merger, including obtaining stockholder and regulatory approvals; (iii) the

merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the merger

on the ability of Standard BioTools or SomaLogic to retain and hire key personnel and maintain relationships with

customers, suppliers and others with whom Standard BioTools or SomaLogic does business, or on Standard BioTools'

or SomaLogic's operating results and business generally; (v) Standard BioTools' or SomaLogic's respective businesses

may suffer as a result of uncertainty surrounding the merger and disruption of management's attention due to the merger; (vi) the

outcome of any legal proceedings related to the merger or otherwise, or the impact of the merger thereupon; (vii) Standard BioTools or SomaLogic may

be adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other

circumstances that could give rise to the termination of the merger agreement and the merger; (ix) restrictions during the pendency

of the merger that may impact Standard BioTools' or SomaLogic's ability to pursue certain business opportunities or strategic

transactions; (x) the risk that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory

approvals required for the merger, or that required governmental and regulatory approvals may delay the consummation of the merger or

result in the imposition of conditions that could reduce the anticipated benefits from the merger or cause the parties to abandon the

merger; (xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized

or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological

changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the merger; (xiv) the

risk that post-closing integration of the merger may not occur as anticipated or the combined company may not be able to achieve the benefits

expected from the merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company's

existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market